Assistant Professor, Medicine - Hematology, Stanford University Medical Center
Hematology
Dr. Bruno C. Medeiros, MD
|
|
Give Review
Doctor Bruno C. Medeiros, MD works in the field of Hematology. He received awards:"CMS Meaningful Use Stage 1 Certification". Bruno C. Medeiros is a published doctor as well. He has 35 publications published. The latest was: Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California.
Publications
- Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California.
- Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis.
- Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.
- Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
- Chemotherapy dose in obese AML patients: To cap or not to cap?
- G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloprolif...
- Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.
- Polypharmacy in AML: The tip of the Iceberg.
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.
- Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia.
- Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
- A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.
- CD11b expression and MK+ AML: A sign of impending doom?
- Phase 2 trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.
- "It doesn't matter if you're black or white", does it?
- Treatment advances have not improved the early death rate in acute promyelocytic leukemia.
- Multiple myeloma.
- Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia.
- Impact of residual normal metaphases in core binding factor acute myeloid leukemia.
- Personalized medicine for acute myelogenous leukemia-At the entrance gate.
- Microfluidic purification and analysis of hematopoietic stem cells from bone marrow.
- Cytarabine dose for acute myeloid leukemia.
- Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
- Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience.
- Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
- Role of CEBPA in normal karyotype acute myeloid leukemia.
- Comparing apples and oranges in normal karyotype acute myeloid leukemia.
- Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic s...
- Graphium basitruncatum fungemia in a patient with acute leukemia.
- Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
- Presence of t(1;14)(p13;p11.2) in Philadelphia chromosome-negative cells in a patient with chronic myeloid leukemia.
- Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin treatment for hepatitis C.
- European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoiet...
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Colorado -
University of Connecticut -
Federal University of Parana Faculty of Medicine
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1760420657 | |
| NPPES Provider LastName | MEDEIROS | |
| NPPES Provider FirstName | BRUNO | |
| NPPES Provider ZIPCode | 943055101 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 276.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1760420657 |
| Last Name Of The Provider | MEDEIROS |
| First Name Of The Provider | BRUNO |
| View All |
Similar Doctors
|
|
Dr. Michael Z. Koontz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence L. Leung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter L. Greenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tamara J. Dunn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley L. Schrier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James L. Zehnder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven E. Coutre, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Bernard A. Cooper, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emily E. Johnston, MD |
|
|
Dr. Sarah M. Smith, MD |